GTCM
MYGN icon

Gyon Technologies Capital Management’s Myriad Genetics MYGN Stock Holding History

Gyon Technologies Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-12,610
Closed -$229K – 535
2022
Q2 		$229K Buy
+12,610
New +$262K 0.06% 363

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Gyon Technologies Capital Management's MYGN Position: Q3 2022 in Review

Gyon Technologies Capital Management sold out of Myriad Genetics (MYGN) in Q3 2022, closing a stake of 12,610 shares — an estimated $229K sold.

Gyon Technologies Capital Management first reported a position in MYGN in Q2 2022 and held it in 1 quarter. The position peaked at $229K in Q2 2022. 191 funds tracked by Wall St. Rank hold MYGN as of Q3 2022.

  • Gyon Technologies Capital Management reported no remaining Myriad Genetics position as of Q3 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 12,610 Myriad Genetics shares in Q3 2022, an estimated $229K.
  • Gyon Technologies Capital Management first reported a position in Myriad Genetics in Q2 2022 and held it in 1 quarter.
  • Gyon Technologies Capital Management's Myriad Genetics position peaked at $229K in Q2 2022.
  • 191 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.